Siemens introduces Sonoline upgrades
Siemens Medical Systems’ ultrasound group in June introduced upgrades to its Sonoline Sienna ultrasound system, expanding the unit’s applications to include surgical and intensive care uses. The company unveiled five new transducers for its
Siemens Medical Systems ultrasound group in June introduced upgrades to its Sonoline Sienna ultrasound system, expanding the units applications to include surgical and intensive care uses. The company unveiled five new transducers for its Sonoline Sienna 2.0 unit for surgery and intensive care environments. The transducers will allow physicians to use Sonoline Sienna for traditional open surgeries, ultrasound-guided biopsies and aspiration procedures, and laparoscopies.
The four interventional transducers7.5L50, 7.5L50-Q, Lb5-2 Biopsy Linear Array, and LAP 8-4are smaller and lighter and carry higher resolution than other transducers, and were developed for such indications as vascular imaging. Issaquah, WA-based Siemens developed its fifth transducer, C8-5, for neonatal intensive care.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
